A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Summary

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Timeline

Start

2026-03-23

Primary completion

2030-07

Completion

2030-07

Drugs

Indications